Physician profile
Jeffrey M Saylor
NPI 1174589410
$9,100.36
in general payments reported to CMS, 2019-2025
59 companies · $1,310 in 2025
The $1,310 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,178 · 2020: $753 · 2021: $1,278 · 2022: $2,013 · 2023: $1,499 · 2024: $1,069 · 2025: $1,310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,877.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,566.10 | 2020-2025 | Vraylar, Qulipta, Ubrelvy |
| Pfizer INC. | $844.48 | 2019-2025 | |
| Glaxosmithkline, LLC. | $811.48 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Teleflex LLC | $558.90 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $533.34 | 2019-2025 | Xifaxan, Relistor, Trulance |
| Amgen INC. | $444.53 | 2019-2025 | Otezla, Repatha, Otezla |
| Merck Sharp & Dohme LLC | $403.96 | 2019-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Otsuka America Pharmaceutical, INC. | $350.85 | 2022-2025 | Rexulti, Nuedexta |
| Amarin Pharma, INC. | $339.03 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $239.37 | 2019-2022 | |
| Allergan, INC. | $231.20 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $230.42 | 2019-2025 | Farxiga, Breztri |
| Lilly USA, LLC | $202.87 | 2019-2025 | Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $191.03 | 2022-2025 | |
| Dexcom, INC. | $171.89 | 2022-2025 | Dexcom G6 Transmitter |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Saylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.